Patents
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
06/2004
06/01/2004US6743459 Oil phase containing a diacylglycerol and a crystallization inhibitor; excellent shelf-life at low temperatues, good in appearance and flavor, useful as a diet or food for improving lipid metabolism
06/01/2004US6743448 Fineness particle size; hormone replacement therapy
06/01/2004US6743447 Pulverulent mannitol and process for preparing it
06/01/2004US6743446 Sustained release
06/01/2004US6743445 Low temperature coatings
06/01/2004US6743442 Bioavailability; sustained release
06/01/2004US6743441 Controlling concentration; side effect reduction
06/01/2004US6743436 Anesthetic composition for intravenous injection comprising propofol
06/01/2004US6743415 Delivery of anti-migraine compounds through an inhalation route
06/01/2004US6743414 Bone disorders; osteoporosis
06/01/2004US6743413 Suspension aerosol formulations
06/01/2004US6742646 Systems, methods and apparatuses for manufacturing dosage forms
06/01/2004CA2315871C Methods, compositions, and kits for enhancing female sexual desire and responsiveness
06/01/2004CA2295108C Method of enhancing magnesium absorption and prevention of atherosclerosis
06/01/2004CA2289648C Conjugated linoleic acid compositions
06/01/2004CA2270004C Stable mitoxantrone solutions
05/2004
05/27/2004WO2004044222A2 Polymeric prodrugs of vancomycin
05/27/2004WO2004044184A1 Biological carriers for the delivery of proteins or peptides
05/27/2004WO2004044011A2 Combinatorial libraries of monomer domains
05/27/2004WO2004044006A1 Conjugates of interleukin-10 and polymers
05/27/2004WO2004043993A2 Novel ampiphilic fluorocarbon molecular vectors for biomedical and medical use
05/27/2004WO2004043503A1 Thrombin-carrying bioabsorbable synthetic nonwoven fabric
05/27/2004WO2004043493A1 Prodrugs built as multiple self-elimination-release spacers
05/27/2004WO2004043492A1 Method for the selective and quantitative functionalization of immunoglobulin fab fragments, conjugate compounds obtained with the same and compositions thereof
05/27/2004WO2004043489A1 Method of obtaining conjugate vaccines and vaccine compositions containing same
05/27/2004WO2004043487A1 Agents for the diagnosis and treatment of tumours that expose altered proteins on the cell surface
05/27/2004WO2004043486A1 An acqueous pharmaceutical formulation comprising the thrombin inhibitor melagatran and use of the formulation in the manufacture of a medicament for use by nasal administration in treating thromboembolism
05/27/2004WO2004043449A1 Pharmaceutical pellets comprising tamsulosin and a process for making the same
05/27/2004WO2004043448A1 Pharmaceutical pellets comprising tamsulosin
05/27/2004WO2004043439A1 Improved formulations containing substituted imidazole derivatives
05/27/2004WO2004043438A1 Shape-retentive hydrogel particle aggregates and their uses
05/27/2004WO2004043436A1 Medicinal aerosol comprising plant essential oil and its preparation
05/27/2004WO2004043432A2 Controlled release depot formulations
05/27/2004WO2004043400A2 Peptide deformylase activated prodrugs
05/27/2004WO2004043396A2 Modified carbamate-containing prodrugs and methods of synthesizing same
05/27/2004WO2004043390A2 Pharmaceutical compositions and methods of using taxane derivatives
05/27/2004WO2004043389A2 Methods of treating cancer and related methods
05/27/2004WO2004043375A2 Pharmaceutical compositions and methods of using taxane derivatives
05/27/2004WO2004043363A2 Protein-stabilized liposomal formulations of pharmaceutical agents
05/27/2004WO2004043357A2 Method of making, and the use of cytotoxic agents containing elemental selenium
05/27/2004WO2004043347A2 Calcitonin drug-oligomer conjugates, and uses thereof
05/27/2004WO2004043331A2 Dermastick thickened ointment
05/27/2004WO2004043146A2 Composition and method for mammary disinfection during winter conditions
05/27/2004WO2004024187A3 Compositions to reduce congestion and methods for application thereof to the nasal membrane
05/27/2004WO2004021968A3 Solution for ungual application
05/27/2004WO2004012735A3 New effector conjugates, process for their production and their pharmaceutical use
05/27/2004WO2004009125A3 Bisacyloxypropylcysteine conjugates and the use thereof
05/27/2004WO2004007520A3 Methods and compositions for preventing oxidative degradation of proteins
05/27/2004WO2004004725A3 Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
05/27/2004WO2004001051A3 Recombinant measles viruses expressing epitopes pf antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions
05/27/2004WO2003099992A3 Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
05/27/2004WO2003082926A9 Antimicrobial polymer conjugates
05/27/2004WO2003070888B1 Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid
05/27/2004WO2003065928A9 Therapeutic polyesters and polyamides
05/27/2004WO2003014155A3 Labelled conjugates of p17 protein and their use in aids diagnosis
05/27/2004WO2003006034A3 Herbal formulation
05/27/2004WO2003000295A3 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
05/27/2004WO2002085304A3 Proliposomal drug delivery system
05/27/2004WO2002079393A3 Dynamic action reference tools
05/27/2004WO2002055721B1 Modular transfection systems based on nucleoprotein filaments
05/27/2004US20040102759 Method of treating coronary arteries with perivascular delivery of therapetic agents
05/27/2004US20040102607 Trimeric antigenic O-linked glycopeptide conjugates, methods of preparation and uses thereof
05/27/2004US20040102520 Use of (r) - ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs
05/27/2004US20040102476 High concentration formulations of opioids and opioid derivatives
05/27/2004US20040102475 Methods for treatment of erectile dysfunction
05/27/2004US20040102445 Synergistic mixture; hypotensive agents for eyes
05/27/2004US20040102429 Zinc salt compositions for the prevention of dermal and mucosal irritation
05/27/2004US20040102422 Administering human papillomaviruse protein; urogenital cancer therapy
05/27/2004US20040102408 Method and medicament for inhibiting the expression of a given gene
05/27/2004US20040102382 Targeting peptides
05/27/2004US20040102381 Methods of altering the binding affinity of a peptide to its receptor
05/27/2004US20040102380 Method for continuous, automated blending of solutions from acids and bases
05/27/2004US20040102373 Protein-induced morphogenesis
05/27/2004US20040102369 Transport of basic fibroblast growth factor across the blood brain barrier
05/27/2004US20040102366 A homogeneous cyclosporin solution comprising a carrier dialkyl ester of aliphatic or aromatic dioic acid, hydrophilic lipophilic balance, forming emulsions in stomach with gastrointestinal fluids
05/27/2004US20040102358 Composition for treating skin conditions
05/27/2004US20040102328 Thermo-stable bio-matrix
05/27/2004US20040101941 Intracellular delivery system for protein phosphatases
05/27/2004US20040101932 Compositions and methods for targeted enzymatic release of cell regulatory compounds
05/27/2004US20040101904 Delivery of pharmaceutical agents via the human insulin receptor
05/27/2004US20040101892 Nucleic acid labeling compounds
05/27/2004US20040101582 Ketamine, gabapentin and clonidine
05/27/2004US20040101573 Injectable composition for cancer treatment
05/27/2004US20040101568 Microgranules based on active principle and method for making same
05/27/2004US20040101566 Novel benzoyl peroxide compositions
05/27/2004US20040101562 Enzyme encapsulated in hydrophilic low melting polymer; bioavailability
05/27/2004US20040101558 Drug with enteric coating; oral administering
05/27/2004US20040101557 Sustained release of active materials; storage stability
05/27/2004US20040101552 Pharmaceutical compositions
05/27/2004US20040101551 Transdermal therapeutic system for releasing venlafaxine
05/27/2004US20040101550 Transdermal therapeutic system
05/27/2004US20040101538 Synergistic mixture of terbinafine with diclofenac or indomethacin; fungicide
05/27/2004US20040101536 Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group B streptococcal carbohydrates
05/27/2004US20040101506 Composition for the prevention and treatment of inflammation of the ear
05/27/2004US20040101495 Method for improving dental health
05/27/2004US20040101487 Combinations of formoterol and fluticasone propionate for asthma
05/27/2004US20040101484 Nasal delivery of apomorphine in combination with glycol derivatives
05/27/2004US20040101483 Mixture of drug with aerosol propellant; supplying lungs
05/27/2004US20040101480 Injectable foam; blood dispersion of gases; cardiovascular disorders
05/27/2004DE10253591A1 Use of polymers of basic amino group-containing monomers, e.g. N-vinyl-imidazole, as additives for cosmetic, dermatological or pharmaceutical formulations, especially delayed-release salicylic acid preparations